News about Insight Medbotics, our technology and our team.

What urologists working in a range of clinical settings, such as Hoag’s Dr. Jeffrey C. Bassett, are teaching us about the need for greater precision in prostate cancer care.

Insight Medbotics announced November 13, 2025, that independent urologists have given its next-generation robotics system, Glenn™, strong and positive feedback on its early design and usability. The feedback was shared through a series of private, invitation-only meetings during the Large Urology Group Practice Association’s (LUGPA) Annual Meeting in Chicago.

Insight Medbotics CEO and Board of Directors member Fazila Seker spoke at TechTO's Health Toronto event on September 10, 2025. Her talk, “The Craft of Building Traction for your MedTech Startup: Untold Stories from the Road Less Traveled,” is available to watch on YouTube.

‍Insight Medbotics is an interventional oncology company advancing precision in cancer care through its MRI-compatible robotics. IGAR, the company’s flagship MRI-compatible robot, has been clinically demonstrated. As the only company to receive a FDA 510(k) clearance for use of a robot with an MRI, Insight Medbotics is now advancing the technology to improve the standard of precision in prostate cancer care.

Insight Medbotics, an interventional oncology company advancing precision in cancer care through its MRI-compatible robotics, is pleased to welcome Dr. Preston Sprenkle, an Associate Professor of Urology at Yale University, to the company’s clinical advisory board.

System leveraging 510k-cleared IGAR technology attracts growing interest from urologists across U.S. hospitals and private practices

Insight Medbotics CEO and Board of Directors member Fazila Seker was among the healthcare leaders speaking at TechTO’s Health Toronto event on September 10, 2025. Her talk, “The Craft of Building Traction for your MedTech Startup: Untold Stories from the Road Less Traveled,” helped builders in the audience to understand their target customers, how industry alliances work, and gain the insight needed to create traction in a challenging technology market.

We’ve had an exciting summer at Insight Medbotics. Our team has achieved several new milestones, which include completing a new robotics system in the urology space. Designed for MRI compatibility while improving the standard of precision in prostate cancer care, this robotics system offers urologists intuitive MRI access to address the guesswork of traditional ultrasound guidance.

Insight Medbotics, an interventional oncology company advancing precision in cancer care through its MRI-compatible robotics, is pleased to announce that it has joined NVIDIA Inception, a program that nurtures startups revolutionizing industries with technological advancements.

Insight Medbotics, an interventional oncology company advancing precision in cancer care through its MRI-compatible robotics, is pleased to announce that Dr. Edward Matsumoto, a urology expert whose clinical practice uses advanced, minimally-invasive approaches in urologic surgery, has joined the company’s Board of Directors.